Medical Marijuana, Inc. the first-ever publicly traded cannabis company in the United States that launched the world’s first-ever cannabis-derived nutraceutical products, brands and supply chain, announced today that Raul Elizalde, the President of its subsidiary HempMeds® Mexico and Latin American operations, will be a keynote speaker at HempToday™’s Latin American & Caribbean Hemp Summit on Nov. 8-9 in Montevideo, Uruguay.
“I am very excited to speak at this event and help people understand the current and potential upcoming legislation on cannabis in Mexico,” Elizalde said. “We want everyone to understand the laws that will soon differentiate marijuana from hemp and help expand access to legal CBD products.”
According to Grandview Research analysts, Mexico’s medical cannabis market size was valued at $47.3 million in 2018. With the new cannabis legislation introduced in Mexico’s Senate this past month, Arcview Research estimates that if cannabis becomes recreationally legal in Mexico, the country’s medical and recreational cannabis markets combined could be worth more than $1 billion by 2024.
The event will feature educational panels on investing, cultivation and harvesting, cannabidiol (CBD), food and beverage, health and beauty, textiles, building materials, hemp machinery and technology, import and export regulations and innovative cannabis research. In addition to Elizalde’s presentation, other key industry leaders from Germany, Uruguay, the United States, Argentina, Colombia, Chile, the Czech Republic, and several other countries will be presenting on a variety of educational topics.
Since the establishment of HempMeds® Mexico, the company has worked to promote access to CBD products by supporting nonprofit organizations that help provide quick access and by working with the government to establish an importation process that allows patients to get Real Scientific Hemp Oil-X™ (RSHO-X™) with ease. HempMeds® Mexico was also the first company to receive a COFEPRIS federal government import permit for a cannabis product, RSHO-X™, for a medical indication.
“Raul is a well-respected leader who is frequently invited to speak at events in Latin America and internationally. In 2017, he spoke at the World Health Organization (WHO)’s annual Expert Committee on Drug Dependence (ECDD) meeting and explained why CBD should not be a controlled substance and should be classified as a supplement,” said Medical Marijuana, Inc. CEO Dr. Stuart Titus. “This conference is a great opportunity for him to share his expert knowledge and vision for cannabis legislation in Mexico.”